Effective Treatment of Pancreatic Tumors with Two Multimutated Herpes Simplex Oncolytic Viruses

Journal of Gastrointestinal Surgery

Volumn 4, Issue 6, 2000, Pages 580-588

  McAuliffe, Priscilla F ^a   Jarnagin, William R ^a   Johnson, Paul ^c   Delman, Keith A ^a   Federoff, Howard ^b   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c NeuroVir Therapeutics Inc ^*  (United States)

Author keywords

G207; Gene therapy; Herpes simplex virus; HSV 1; HSV 2; NV1020; Pancreatic carcinoma; R7020

Indexed keywords

ADENOCARCINOMA; ANIMAL; ARTICLE; CELL CULTURE; CELL SURVIVAL; COMPARATIVE STUDY; DISEASE MODEL; EXPERIMENTAL NEOPLASM; FEMALE; GENE THERAPY; GENETICS; HERPES SIMPLEX; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; MALE; METHODOLOGY; MOUSE; NUDE MOUSE; NUDE RAT; PANCREAS TUMOR; PROBABILITY; RAT; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; VIROLOGY; VIRUS;

ADENOCARCINOMA; ANIMALS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; HERPES SIMPLEX; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; PROBABILITY; RATS; RATS, NUDE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED; VIRUSES;

EID: 0034331115     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(00)80106-7     Document Type: Article

References (31)

1. DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practices of Oncology, 3rd ed, Philadelphia; JB Lippincott, 1989.
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. Ca Cancer J Clin 2000;50:7-33.
3. Felzmann T, Ramsey WJ, Blaese RM. Characterization of the anurumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Ther 1997;4:1322-1329.
4. Okada H, Giezeman-Smits KM, Tahara H, Attanucci J, Fellows WK, Lotze MT, Chambers WH, Bozik ME. Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine. Gene Ther 1999;6:219-226.
5. DiMain JM, Clary BM, Via DF, Coveney E, Pappas TN, Lyerly HK, Directed enzyme prodrug gene therapy for pancreatic cancer in vivo. Surgery 1994;116:205-213.
6. Aghi M, Kramin CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies, J Natl Cancer Inst 1998;90:370-380.
7. Timiryasova TM, Chen B, Haghighat P, Fodor I. Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis. Int J Oncol 1999;14:845-854.
8. Cooper MJ, Lippa M, Payne JM, Hatzivassiliou G, Reifenberg E, Fayazi B, Perales JC, Morrison LJ, Templeton D, Piekarz RL, Tan J. Safety-modified episomal vectors for human gene therapy. Proc Natl Acad Sci USA 1997;94:6450-6455.
9. Lorence RM, Rood PA, Kelley KW. Newcastle disease virus as an antineoplastic agent: Induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst 1988;80:1305-1312.
10. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nyc J, Sampson-Johannes A, Fartaey A, McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-376.
11. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect Dis 1998;26:541-555.
12. Pechan PA, Herrlinger U, Aghi M. Jacobs A, Breakefield XO. Combined HSV-1 recombinant and amplicon piggyback vectors: Replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. J Gene Med 1999; 1:176-185.
13. Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett EH, Chiocca EA, Breakefield XO. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997;8:2057-2068.
14. Ynon SS, Nakanmra H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK. An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 2000;14:301-311.
15. Martuza RL, Malick A, Mackert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991;252:854-856.
16. Carew JF, Kooby DA, Halterman MW, Federoff HJ, Fong Y. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 1999;10:1599-1606.
17. Kooby DA, CarewJF, Halterman MW, Mack JF, Bertino JR, Blumgart LH, Federoff HJ, Fong Y. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207). FASEB J 1999; 13:1325-1334.
18. Lee JH, Federoff HJ, Schoeniger LO. G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro. J GASTROINTEST SURG 1999;3:127-133.
19. Bennett JJ, Kooby DA, Delman K, McAuliffe P, Halterman MW, Federoff H, Fong Y. Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J Mol Med 2000;78:166-174.
20. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-943.
21. Markert JM, Malick A, Coen B, Martuza RL, Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir. Neurosurgery 1993;32:597-603.
22. Meignier B. Genetically engineered attenuated herpes simplex viruses. Rev Infect Dis 1991;13:S895-S897.
23. KucharczukJC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH, Rizk NP, Molnar-Kimber KL, Brown SM, MacLean AR, Litzky LA, Fraser NW, Albelda SM, Keiser LR. Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997;57: 466-471.
24. Walker JR, McGeagh KC, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999; 10:2237-2243.
25. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998;9:2177-2185.
26. Advani SJ, Chung S, Yan SY, Gillespie GY, Markert JM, Whitley RJ, Roizman B, Weichselbaum RR. Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human solid tumors. Cancer Res 1999;59:2055-2058.
27. 134.5 gene. J Neurovirol 1997;3(Suppl 1): S1-S2.
28. Roizman B. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors. Proc Nat Acad Sci 1996;93:11307-11312.
29. Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ, Rabkin SD. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999;73:6319-6326.
30. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents. J Infect Dis 1988;158:602-614.
31. Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivigatus). J Infect Dis 1990;162:313-321.